| Literature DB >> 24141227 |
Zhiwei Qin1, Sheng Huang, Yi Yu, Hai Deng.
Abstract
Dithiolopyrrolones are a class of antibiotics that possess the unique pyrrolinonodithiole (4H-[1,2] dithiolo [4,3-b] pyrrol-5-one) skeleton linked to two variable acyl groups. To date, there are approximately 30 naturally occurring dithiolopyrrolone compounds, including holomycin, thiolutin, and aureothricin, and more recently thiomarinols, a unique class of hybrid marine bacterial natural products containing a dithiolopyrrolone framework linked by an amide bridge with an 8-hydroxyoctanoyl chain linked to a monic acid. Generally, dithiolopyrrolone antibiotics have broad-spectrum antibacterial activity against various microorganisms, including Gram-positive and Gram-negative bacteria, and even parasites. Holomycin appeared to be active against rifamycin-resistant bacteria and also inhibit the growth of the clinical pathogen methicillin-resistant Staphylococcus aureus N315. Its mode of action is believed to inhibit RNA synthesis although the exact mechanism has yet to be established in vitro. A recent work demonstrated that the fish pathogen Yersinia ruckeri employs an RNA methyltransferase for self-resistance during the holomycin production. Moreover, some dithiolopyrrolone derivatives have demonstrated promising antitumor activities. The biosynthetic gene clusters of holomycin have recently been identified in S. clavuligerus and characterized biochemically and genetically. The biosynthetic gene cluster of thiomarinol was also identified from the marine bacterium Pseudoalteromonas sp. SANK 73390, which was uniquely encoded by two independent pathways for pseudomonic acid and pyrrothine in a novel plasmid. The aim of this review is to give an overview about the isolations, characterizations, synthesis, biosynthesis, bioactivities and mode of action of this unique family of dithiolopyrrolone natural products, focusing on the period from 1940s until now.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24141227 PMCID: PMC3826145 DOI: 10.3390/md11103970
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
A summary of naturally occurring dithiolopyrrolone antibiotics.
| NO. | Name | Structure | Source | Ref. | ||
|---|---|---|---|---|---|---|
| R1 | R2 | R3 | ||||
| Aureothricin | CH3CH2CO | H | CH3 | [ | ||
| Thiolutin | CH3CO | H | CH3 |
| [ | |
| Isobutanoylpyrrothine | (CH3)2CHCO | H | CH3 |
| [ | |
| Butanoylpyrrothine | CH3(CH2)2CO | H | CH3 |
| [ | |
| Senecioylpyrrothine | (CH3)2C=CHCO | H | CH3 |
| [ | |
| Tigloylpyrrothine | (CH3)CH=C(CH3)CO | H | CH3 |
| [ | |
| Xenorhabdin 4 | CH3(CH2)4CO | H | CH3 | [ | ||
| Xenorhabdin 5 | (CH3)2CH(CH2)3CO | H | CH3 | [ | ||
| Holomycin | CH3CO | H | H | [ | ||
| CH3CH2CO | H | H | [ | |||
| vD844 | CHO | CH3 | H | [ | ||
| Xenorhabdin 1 | CH3(CH2)4CO | H | H | [ | ||
| Xenorhabdin 2 | (CH3)2CH(CH2)3CO | H | H | [ | ||
| Xenorhabdin 3 | CH3(CH2)6CO | H | H | [ | ||
| Xenorhabdin 8 | decanoyl | H | H | [ | ||
| Xenorhabdin 9 | dodecanoyl | H | H | [ | ||
| Xenorhabdin 10 | H | H | [ | |||
| Xenorhabdin 11 | H | H | [ | |||
| Xenorhabdin 12 | H | H | [ | |||
| Xenorhabdin 13 | H | H | [ | |||
| Thiomarinol A | Marinolic acids A | H | H | [ | ||
| Thiomarinol B | Marinolic acids B | H | H | [ | ||
| Thiomarinol C | Marinolic acids C | H | H | [ | ||
| Thiomarinol D | Marinolic acids D | H | H | [ | ||
| Thiomarinol E | Marinolic acids E | H | H | [ | ||
| Thiomarinol F | Marinolic acids F | H | H | [ | ||
| Thiomarinol G | Marinolic acids G | H | H | [ | ||
Figure 1N-methyl, N-acylpyrrothine derivatives.
Figure 2N-acylpyrrothine derivatives.
Figure 3Thiomarinols, hybrid antibiotic natural products.
Biological activities of dithiolopyrrolones.
| Organism | Thiolutin | Holomycin | Thiomarinol | |
|---|---|---|---|---|
| MIC (μg/mL)/IC50 (μM) | ||||
| G+ | <0.2 | NC | NC | |
| 2 | NC | NC | ||
| <0.2 | NC | NC | ||
|
| 20 | 4 | <0.01 | |
| G− |
| 1 | 8 | 0.78 |
|
| >100 | <2 | 3.13 | |
|
| >100 | NC | NC | |
|
| >100 | 64 | 0.39 | |
|
| NC | 4 | NC | |
|
| NC | <0.3 | NC | |
| Fungi | 10 | NC | NC | |
| 20 | NC | NC | ||
| 20 | NC | NC | ||
|
| <40 | NC | NC | |
|
| 20 | NC | NC | |
| Yeast |
| 10 | NA | NC |
| HUVEC | VTN | 0.83 | NC | NC |
| FN | 0.16 | NC | NC | |
| COL | 0.48 | NC | NC | |
Microbials were tested as MIC and HUVEC were tested as IC50 values. NC, unclear; NA, no activity; HUVECs, human umbilical vein endothelial cell; VTN, vitronectin; FN, fibronectin; COL, collagen type IV.
Scheme 1Lukas’s synthesis of holomycin.
Scheme 2Ellis’s synthesis of holomycin (9) and its carboxylated derivative (9a’).
Scheme 3Hjelmgaard’s synthesis of holomycin and its derivatives.
Scheme 4Stachel’s synthesis of dithiolopyrrolones.
Scheme 5Li’s synthesis of dithiolopyrrolone derivatives.
Figure 4“Unnatural” dithiolopyrrolone natural products using precursor-directed biosynthesis.
Figure 5Comparison of the genetic organization of the holomycin biosynthetic gene clusters from S. clavuligerus, Y. ruckeri and Pseudoalteromonas, respectively.
Deduced functions of open reading frames (ORFs) that were predicted to be involved in the biosynthesis of holomycin in S. clavuligerus, Y. ruckeri and Pseudoalteromonas, respectively.
| ORFs in | Homolog in | Homolog in | Proposed Function |
|---|---|---|---|
| ORF3489(HlmF) | Hom1 (61%) | HolG (72%) | PPC-DC decarboxylase |
| ORF3490(HlmG) | Hom2(65%) | HolF (70%) | Globin |
| ORF3483(HlmA) | Hom3 (38%) | HolE (45%) | |
| ORF3485(HlmB) | Hom4 (58%) | HolD (63%) | Acyl-CoA dehydrogenase |
| ORF3486(HlmC) | Hom5 (36%) | HolC (42%) | Thioesterase |
| ORF3487(HlmD) | Hom6 (47%) | HolB (59%) | FMN-dependent oxdioreductase |
| ORF3488(HlmE) | Hom7 (47%) | HolA (55%) | NRPS (Cy-A-T) |
| ORF3491(HlmH) | Hom8 (61%) | MFS efflux protein |
Scheme 6Biochemical study confirmed that the N-acetyl-CoA transferase ORF3483 is responsible for the amid bond formation at the late stage of the holomycin biosynthesis in Streptomyces clavuligerus.
Scheme 7Biochemical study confirmed that the dithiol oxidase HlmI is responsible for the disulfide bond formation using molecular oxygen as a cofactor.
Scheme 8Proposed biosynthetic pathway of holomycin.
Scheme 9Proposed biosynthetic pathway of thiomarinol A.